Trial Profile
A Phase I, Open-Label, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intra-anal Application of Topical Oxymetazoline Gel in Healthy Adult Volunteers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Oxymetazoline (Primary)
- Indications Faecal incontinence
- Focus Pharmacokinetics
- Sponsors 9 Meters Biopharma [CEASED]; RDD Pharma
- 31 Jul 2022 Planned number of patients changed from 20 to 40.
- 31 Jul 2022 Planned End Date changed from 1 May 2020 to 1 Dec 2023.
- 31 Jul 2022 Planned primary completion date changed from 1 Apr 2020 to 1 Dec 2023.